Flputnam Investment Management Co. Sells 67,582 Shares of Gilead Sciences, Inc. $GILD

Flputnam Investment Management Co. lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 48.8% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 70,944 shares of the biopharmaceutical company’s stock after selling 67,582 shares during the quarter. Flputnam Investment Management Co.’s holdings in Gilead Sciences were worth $8,963,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Persistent Asset Partners Ltd bought a new position in shares of Gilead Sciences during the second quarter valued at approximately $25,000. Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences in the fourth quarter valued at $25,000. Kimelman & Baird LLC purchased a new position in Gilead Sciences during the 2nd quarter valued at $25,000. Vermillion & White Wealth Management Group LLC increased its position in Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 85 shares during the period. Finally, Quattro Advisors LLC bought a new position in Gilead Sciences in the 4th quarter worth $26,000. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on GILD shares. Truist Financial dropped their target price on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Rothschild & Co Redburn lowered their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Leerink Partners cut Gilead Sciences from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $146.00 to $127.00 in a research report on Tuesday, July 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 target price on shares of Gilead Sciences in a report on Wednesday, August 5th. Twenty-four analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $158.04.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $138.36, for a total value of $415,080.00. Following the completion of the transaction, the chief financial officer directly owned 165,646 shares of the company’s stock, valued at approximately $22,918,780.56. The trade was a 1.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the transaction, the chief executive officer owned 592,133 shares in the company, valued at approximately $77,160,851.23. This represents a 2.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 105,000 shares of company stock worth $14,238,120 over the last quarter. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Trading Down 2.1%

NASDAQ:GILD opened at $145.68 on Friday. Gilead Sciences, Inc. has a one year low of $108.46 and a one year high of $157.29. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The company’s 50-day simple moving average is $134.25 and its 200 day simple moving average is $136.62. The firm has a market capitalization of $180.64 billion, a P/E ratio of -54.56 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.25) by $0.50. The firm had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business’s revenue was up 10.6% on a year-over-year basis. During the same period last year, the business earned $2.01 earnings per share. As a group, analysts forecast that Gilead Sciences, Inc. will post -0.5 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. Gilead Sciences’s dividend payout ratio (DPR) is presently -122.85%.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The FDA approved Bixlenvo, a once-daily single-tablet regimen combining bictegravir and lenacapavir for virologically suppressed adults with HIV. It is the first and only single-tablet option for patients on complex regimens who cannot use currently available alternatives, potentially expanding Gilead’s HIV franchise and supporting its longer-term lenacapavir strategy. Reuters FDA approval article
• Positive Sentiment: The European Commission approved Trodelvy plus Keytruda for certain first-line metastatic triple-negative breast cancer patients, strengthening Gilead’s oncology portfolio and adding a potential growth opportunity outside its core HIV business. EU Trodelvy approval article
• Neutral Sentiment: Analysts remain broadly constructive, with a consensus “Moderate Buy” rating and an average price target of approximately $158. However, GILD’s strong multi-year advance may have raised expectations and limited the immediate upside from the Bixlenvo approval. Gilead valuation article
• Negative Sentiment: Director Anthony Welters sold 18,000 shares worth about $2.68 million, reducing his position by roughly 58%. The sale occurred under a pre-arranged Rule 10b5-1 plan, making it a limited bearish signal, but it may still weigh modestly on investor sentiment. SEC insider transaction filing

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.